Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

S&P Consultants Ranked in the Best in KLAS: Software and Services Report for Fourth Consecutive Year

Published

on

Reading Time: 4 minutes

BRAINTREE, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/HealthIT?src=hash” target=”_blank”gt;#HealthITlt;/agt;–With the release of the 2019 Best in KLAS: Software Services report,
S&P Consultants marks the fourth year of being ranked by the
prestigious peer-reviewed healthcare technology organization.

To assemble the report, KLAS talks to thousands of organizations to
gather insight on their implementation experiences with a variety of
vendors and how well those vendors live up to expectations.

“Of the many accolades available to businesses in our sector, this one
is particularly meaningful,” said Andy Splitz, Cofounder and CEO of S&P
Consultants. “That’s because it represents the opinions of our
clients—and their peer set. These are people who have had direct
experience in implementing HIT solutions and working with some of the
best consultants and software vendors in the industry. For them to
single us out this way again this year is not only very gratifying, but
it’s also highly motivating to our hard-working team.”

This year, S&P was rated in the HIT Implementation Support and Staffing
category with a score of 92.9 out of 100.

As part of KLAS’s research, candid and anonymized feedback from
confirmed S&P clients collected. Many of the comments provided by S&P
clients spoke to how our expertise helped all parties in the
implementation achieve their common goal. Here are some highlights1:

  • S&P Consultants helped steer us away from danger and… set us up
    much better for future success

    Director, Project Results –
    Aug 2018.
  • S&P Consultants helped us figure out things that our EHR vendor said
    were impossible. And we and S&P Consultants also figured out other
    things together. That was quite an accomplishment. S&P Consultants
    really did partner with us, and they helped us through the entire
    project.
    Manager, Project Results – Dec 2018
  • I would contract with S&P Consultants again in a heartbeat. We liked
    that they were willing to tell us what we needed to hear. Some of the
    other consultants we have worked with would sometimes tell us what we
    wanted to hear. But S&P Consultants was a little different. I could
    tell right out of the gate that they were up front and that they did
    things in a great manner. They were great about telling us how things
    were. Also, the people that S&P Consultants gave us were tremendous.
    They were head and shoulders above the folks that we were getting from
    another vendor. S&P Consultants has a good methodology. They use a
    methodology and structure for implementations that are based on some
    of their previous engagements. For us, the methodology was a huge
    difference from what we had with another vendor. When we brought S&P
    Consultants into our implementation, there was a night-and-day
    difference. In general, S&P Consultants’ people, framework, and
    ability to have candid conversations were the things that set them
    apart.

    Director, Project – Jan 2019

  • S&P Consultants didn’t come with an attitude of telling us what they
    have done and what we have to do. They actually learned our operation
    as much as possible. They were able to integrate what they knew with
    our workflow. I was really impressed.

    Manager, Tools and
    Methodology – Dec 2018

  • I was struck by the fact that S&P Consultants was able to initiate
    activity and work without having to be told. They weren’t sitting
    around waiting for directions. They integrated with our staff and
    essentially became part of our staff. And they were the subject matter
    experts for us. S&P Consultants worked very closely with our teams,
    and they always had new things that needed to get done. They would
    initiate things.
    Manager, People and Knowledge – Dec 2018
  • The biggest thing that sets S&P Consultants apart is the fact that
    their people are extremely comfortable working in a client’s
    environment. Some consultants just talk around a table in the
    conference room. But S&P Consultants’ people don’t just stay at the
    table. They are out in the trenches working with the team. They go
    where they are needed. That really stands out. They show us how to do
    the things they talk about. The consultants made our folks
    comfortable. Our staff members look forward to the consultants coming
    on-site. People come up to me and ask whether the consultants are
    coming in.
    Manager, People and Knowledge – Dec 2018

Zach Johnson, S&P’s Chief Strategy Officer, lays much of the
firm’s success at the feet of its proven implementation methodology
known as S&P InTegrity™.

“InTegrity is a unique approach to HIT implementations that helps
clients ensure their team’s success, deliver the highest-quality result,
and maximize their ROI. InTegrity gives clients better visibility into
the potential (common) pitfalls that lay in wait for many
implementations. The process also helps client bind strategy to
execution, ensuring that they are leveraging technology to serve both
their clinical and revenue goals at the highest levels. Our approach
adds a level of granularity and client-specificity to the vendor’s
general framework, so that real-world conditions are taken into account.
InTegrity accurately reflects the actual situation, resources,
leadership, objectives and day-to-day reality in a way that greatly
improves the chances for a smooth and successful implementation.”

About S&P Consultants:
S&P Consultants enjoys a 20-year
reputation for “doing the right thing” in healthcare IT, facilitating
realistic interactions among all parties in HIS implementations. Their
InTegrity℠ approach provides a solid “genetic roadmap” and adaptive
framework to organizations looking to assure the success of complex
projects.

About KLAS:
KLAS is a data-driven company on a mission to improve
the world’s healthcare by enabling provider and payer voices to be heard
and counted. Working with thousands of healthcare professionals, KLAS
collects insights on software, services and medical equipment to deliver
reports, trending data and statistical overviews. KLAS data is accurate,
honest and impartial. The research directly reflects the voice of
healthcare professionals and acts as a catalyst for improving vendor
performance. To learn more about KLAS and the insights we provide, visit KLASresearch.com.

1 – Selected commentary collected about S&P Consultants. ©
KLAS 2019 visit https://klasresearch.com
for a complete view.

Contacts

S&P Consultants
Tracey Leathers
781-428-3497
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect

Published

on

Continue Reading

Cannabis

Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand

Published

on

Continue Reading

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

on

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the  seller.

“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to,  the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania